| Sleep Apnea, Obstructive
Zepbound vs Sunosi
Side-by-side clinical, coverage, and cost comparison for sleep apnea, obstructive.Deep comparison between: Zepbound vs Sunosi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSunosi has a higher rate of injection site reactions vs Zepbound based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sunosi but not Zepbound, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zepbound
Sunosi
At A Glance
SC injection
Once weekly
GIP/GLP-1 receptor agonist
Oral
Once daily
DNRI
Indications
- Obesity
- Sleep Apnea, Obstructive
- Narcolepsy
- Sleep Apnea, Obstructive
Dosing
Obesity Starting dose 2.5 mg SC once weekly for 4 weeks, escalating in 2.5 mg increments every 4 weeks; maintenance 5 mg, 10 mg, or 15 mg SC once weekly.
Sleep Apnea, Obstructive Starting dose 2.5 mg SC once weekly for 4 weeks, escalating in 2.5 mg increments every 4 weeks; maintenance 10 mg or 15 mg SC once weekly.
Narcolepsy 75 mg orally once daily upon awakening; may double every 3 days based on efficacy and tolerability; maximum 150 mg once daily.
Sleep Apnea, Obstructive 37.5 mg orally once daily upon awakening; may double every 3 days based on efficacy and tolerability; maximum 150 mg once daily.
Renal Impairment Moderate (eGFR 30-59 mL/min/1.73 m2): start 37.5 mg once daily, may increase to max 75 mg after at least 7 days. Severe (eGFR 15-29 mL/min/1.73 m2): 37.5 mg once daily; maximum 37.5 mg. ESRD: not recommended.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or any excipient in ZEPBOUND
- Concomitant use with MAO inhibitors or within 14 days after discontinuing MAOI treatment due to risk of hypertensive reaction
Adverse Reactions
Most common (>=2%) Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease, flatulence, abdominal distension, dizziness
Serious Risk of thyroid C-cell tumors, severe gastrointestinal reactions, acute kidney injury, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions including anaphylaxis and angioedema, hypoglycemia, diabetic retinopathy complications, pulmonary aspiration
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, pulmonary aspiration, acute renal failure or worsening of chronic renal failure
Most common (>=5%) headache, nausea, decreased appetite, anxiety, insomnia
Serious blood pressure and heart rate increases, psychiatric symptoms
Postmarketing hypersensitivity reactions (rash erythematous, rash, urticaria)
Pharmacology
Tirzepatide is a dual GIP receptor and GLP-1 receptor agonist that selectively binds and activates both receptors, reducing body weight by decreasing caloric intake and affecting appetite regulation, stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and delaying gastric emptying.
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) that inhibits reuptake of dopamine and norepinephrine with no appreciable binding to serotonin transporters or to dopamine, serotonin, norepinephrine, GABA, adenosine, histamine, orexin, or acetylcholine receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zepbound
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Sunosi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
UnitedHealthcare
Zepbound
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Sunosi
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Humana
Zepbound
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (0/3)
Sunosi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/fillfill
Zepbound Savings Card - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Cost estimate not availableAssistance Fund: Narcolepsy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZepboundView full Zepbound profile
SunosiView full Sunosi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.